AliskirenHydrochlorothiazide combination: In mild to moderate hypertension

Drugs

Volumn 69, Issue 7, 2009, Pages 833-841

  Baldwin, Claudine M ^a   Plosker, Greg L ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ALISKIREN PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; PLACEBO; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE;

ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLOOD PRESSURE REGULATION; BORDERLINE HYPERTENSION; BRONCHITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FOOD; FOOD DRUG INTERACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOKALEMIA; INFLUENZA; KIDNEY CLEARANCE; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; OBESITY; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTIGO; BLOOD PRESSURE; DRUG COMBINATION; PATHOPHYSIOLOGY;

AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG COMBINATIONS; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION;

EID: 66149158140     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969070-00004     Document Type: Article

References (28)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-52
2. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007 Jan; 25 (1): 217-26
3. Nickenig G, Simanenkov V, Lembo G, et al. Efficacy of alis- kiren/hydrochlorothiazide single-pill combinations in aliski- ren non-responders. Blood Press 2008; 17 (Suppl. 2): 31-40
4. Novartis. Tekturna HCT® (aliskiren and hydrochlorothia- zide) tablets: prescribing information (US) [online]. Avail- able from URL: http://www.pharma.us.novartis.com/ product/pi/pdf/tekturna-hct.pdf [Accessed 2009 Mar 3]
5. European Medicines Agency. Rasilez HCT: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/ rasilezHCT/H-964-PI-en.pdf [Accessed 2009 Mar 2]
6. Frampton JE, CurranMP.Aliskiren: a review of its use in the management of hypertension. Drugs 2007; 67 (12): 1767-92
7. Fenton C, Keating GM, Scott LJ. Telmisartan/ hydrochlorothiazide: in the treatment of essential hyper- tension. Drugs 2003; 63 (19): 2013-26; discussion 2027-8
8. Langtry HD,McClellan KJ. Valsartan/hydrochlorothiazide. Drugs 1999 May; 57 (5): 751-5; discussion 756-8
9. Croxtall JD, Keating GM. Irbesartan/hydrochlorothiazide in moderate to severe hypertension.Drugs 2008; 68 (10): 1465-72
10. Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hyperten- sion 2002; 39: E1-8
11. Azizi M, Menard J, Bissery A, et al. Pharmacologic de- monstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antago- nist valsartan on the angiotensin II-renin feedback inter- ruption. J Am Soc Nephrol 2004; 15: 3126-33
12. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977 Dec 2; 12 (4): 297-303
13. Pool J, Gradman A, Kolloch R, et al. Aliskiren, a novel rennin inhibitor, provides long-termsuppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension [abstract no. 790]. EurHeart J 2006 Sep; 27 Suppl.: 119. Plus poster presented at theWorld Congress of Cardiology; 2006 Sep 2-6; Barcelona
14. Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007 May; 49 (5): 1047-55
15. Ayalasomayajula S, Yeh CM, Vaidyanathan S, et al. Effects of aliskiren, a direct renin inhibitor, on cardiac repolar- ization and conduction in healthy subjects. J Clin Phar- macol 2008 Jul; 48 (7): 799-811
16. Vaidyanathan S, Jarugula V, Dieterich HA, et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008; 47 (8): 515-31
17. Vaidyanathan S, Limoges D, Yeh C, et al. Aliskiren, an or- ally effective renin inhibitor, shows dose linear pharmaco- kinetics in healthy volunteers [abstract no. PIII-23]. Clin Pharmacol Ther 2006; 79 (2): P64
18. Limoges D, Dieterich HA, Yeh CM, et al. A study of dose- proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther 2008 May; 46 (5): 252-8
19. Waldmeier F, Glaenzel U, Wirz B, et al. Absorption, dis- tribution, metabolism, and elimination of the direct rennin inhibitor aliskiren in healthy volunteers. Drug Metab Dis- pos 2007 Aug; 35 (8): 1418-28
20. Dieterich H, Kemp C, Vaidyanathan S, et al. Pharmacoki- netic interaction of the oral renin inhibitor aliskiren with hydrochlorothiazide in healthy volunteers [abstract no. PI-20]. Clin Pharmacol Ther 2006 Feb; 79 (2): 12
21. PatelRB, PatelUR,RoggeMC, et al. Bioavailability of hydro- chlorothiazide from tablets and suspensions. J Pharm Sci 1984; 73 (3): 359-61
22. Van Tassell BW, Munger MA. Aliskiren for renin inhibi- tion: a new class of antihypertensives. Ann Pharmacother
23. 2007 Mar; 41 (3): 456-64
24. Blumenstein M, Romaszko J, Calderon A, et al. Anti- hypertensive efficacy and tolerability of aliskiren/ hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25mg alone. Curr Med Res Opin 2009; 25 (4): 903-10
25. Gradman AH, Kolloch RE, Meyers M, et al. Aliskiren in combination with hydrochlorothiazide is effective and well tolerated during long-term treatment of hypertension [abstract no. P-384]. J Clin Hypertens (Greenwich) 2007 May; 9 (5 Suppl. A): 160
26. nd Annual High Blood Pressure Conference; 2008 Sep 17; Atlanta (GA)
27. PrescottMF, Boye SW, Le Breton S, et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren when added to hydrochlorothiazide treatment in patients with extreme obesity and hypertension [abstract no. 1014-169]. J Am Coll Cardiol 2007 Mar; 49 (9 Suppl. A): 370. Plus poster presented at the 56th Annual Scientific Session of the American College of Cardiology; 2007 Mar 24; New Orleans (LA)
28. European Medicines Agency. European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/press/pr/ 8952309en.pdf [Accessed 2009 Mar 3]